A Phase Ia/Ib Study of NMS-03597812 in Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia including patients with TP53 mutations

Active:	Yes
Cancer Type:	Leukemia Multiple Myeloma	NCT ID:	NCT06549790
Trial Phases:	Phase I	Protocol IDs:	PERKA-812-003 (primary)
Eligibility:	, Male and Female	Study Type:
Study Sponsor:	Nerviano Medical Sciences
NCI Full Details:	https://clinicaltrials.gov/study/NCT06549790

Summary

The aim of PERKA-812-003 study is to investigate the safety, pharmacokinetics and preliminary anti-tumor activity of treatment with NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who have exhausted standard treatment, including a subset of patients with TP53 mutations. It is anticipated that combination with venetoclax will be further evaluated following a future protocol amendment, once the Recommended Range Dose (RDR) as single agent has been defined.

Treatment Sites in Georgia

Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-851-8523

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.